Patients with rheumatoid arthritis (RA) have high healthcare utilization and high healthcare costs, which place a burden on health systems and patients alike. However, a recently published retrospective cohort study found that effective treatment for RA (namely, treatment with etanercept) may lead to lower overall and lower RA-related healthcare utilization.
Patients with rheumatoid arthritis (RA) have high healthcare utilization and high healthcare costs, which place a burden on health systems and patients alike. However, a recently published retrospective cohort study found that effective treatment for RA (namely, treatment with etanercept) may lead to lower overall and lower RA-related healthcare utilization.
The study, by Neil A. Accortt and colleagues, published in Advances in Therapy, drew data from the Truven Health Analytics MarketScan Database, which includes health insurance claims from employers and health plans across the United States. Data from 6737 patients were analyzed to compare differences in healthcare utilization pre- and post-initiation of the anti—tumor necrosis factor agent etanercept for the period from 2009 to 2014. Study outcomes were evaluated for the 12-month period before and the 12-month period after treatment initiation with the reference etanercept, Enbrel. (While a biosimilar of etanercept has been approved by the FDA, it has not yet launched in the United States.)
The assessment of healthcare utilization included office visits, inpatient admissions, emergency department visits, outpatient services, RA-related procedures, pharmacotherapy, tests, and some comorbidities (RA-related utilization was determined by a diagnosis of RA as the primary diagnosis on claims forms).
The researchers found that use of non-biologic disease-modifying anti-rheumatic drugs (nbDMARD), oral corticosteroids, oral opioid analgesics, and oral non-steroidal anti-inflammatory drugs (NSAID) were significantly lower after etanercept was initiated. The percentage of patients using drugs in each category pre- and post-initiation of etanercept was as follows:
“This observation is notable,” the authors state, “as decreased exposure also reduces the risk of adverse events associated with these medications.”
Overall healthcare utilization also dropped for patients after they initiated etanercept treatment: patients had approximately 1 fewer outpatient service (mean, 22 visits pre-initiation versus 21.4 visits post-initiation), and 1 fewer office visit (mean, 17.1 visits pre-initiation versus 16.2 visits post-initiation). The most compliant patients had, on average, 3 fewer office visits than the least compliant.
The authors concluded that overall healthcare utilization decreased after patients initiated etanercept, and that greater compliance was linked to significantly lower utilization.
The authors note that their study was limited by the fact that claims data have the risk of misclassification or coding errors, as well as by the fact that no data on disease activity or severity were available for the patients in the cohort. However, the study did include a large sample size of patients, and the pre- and post-initiation design of the study allowed patients to act as their own controls.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.